Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Monday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is projected to release its earnings data after the market closes on Monday, February 10th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.42) per share and revenue of $19.05 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Arrowhead Pharmaceuticals Trading Down 1.2 %

Shares of ARWR stock opened at $20.24 on Friday. The stock has a market capitalization of $2.53 billion, a P/E ratio of -4.03 and a beta of 0.95. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The firm’s 50 day moving average is $20.50 and its 200 day moving average is $21.48. Arrowhead Pharmaceuticals has a 12-month low of $17.05 and a 12-month high of $36.72.

Insider Buying and Selling

In other news, CFO Kenneth Allen Myszkowski sold 27,167 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.83, for a total transaction of $538,721.61. Following the completion of the sale, the chief financial officer now owns 473,433 shares of the company’s stock, valued at $9,388,176.39. The trade was a 5.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the transaction, the chief executive officer now directly owns 3,764,252 shares of the company’s stock, valued at approximately $71,709,000.60. This represents a 0.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 147,432 shares of company stock valued at $2,957,986 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ARWR shares. Sanford C. Bernstein cut their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Citigroup lowered their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. Finally, Piper Sandler lowered their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $43.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.